Biotechnology company focused on engineering cells as medicines for a wide range of diseases.
Sana Biotechnology, Inc. is a pioneering biotechnology company dedicated to harnessing the power of engineered cells as therapeutic agents. The company specializes in developing ex vivo and in vivo cell engineering platforms tailored to address critical unmet needs across various medical domains. These include oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and more.
At the forefront of Sana Biotechnology's pipeline are innovative product candidates such as SG295 and SG242, designed to target CD19+ cancer cells prevalent in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The company also advances SG221 and SG239 for the treatment of multiple myeloma, along with SG328 aimed at addressing ornithine transcarbamylase deficiency.
Additionally, Sana Biotechnology is developing SG418 for sickle cell disease and beta-thalassemia, SC291 as a CD19 allogeneic T cell therapy, SC255 targeting multiple myeloma, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. These efforts underscore the company's commitment to tackling complex diseases through cutting-edge cellular engineering approaches.
Founded in 2018 and headquartered in Seattle, Washington, Sana Biotechnology, Inc. was originally known as FD Therapeutics, Inc. before rebranding in September 2018. With a forward-thinking approach and a robust scientific foundation, Sana Biotechnology continues to push the boundaries of biotechnology, aiming to transform patient care and improve outcomes for individuals facing serious and challenging medical conditions.